skip to Main Content

Update on adult access to Spinraza

  • 3 December 2019

During an election period, Government Departments are restricted in the announcements that they are able to make or the information that they are able to publish. The ongoing communication between NHS England and the Patient Advocacy Groups (PAGs) about implementation…

Read More

Physio with Marion Episode 2

  • 25 November 2019

TreatSMA hosted its second Physio with Marion session on Sunday, and thanks to Marion and all of those who took part in asking questions, it was another great success.

Read More

SRK-015 increases muscle strength in people with SMA

  • 21 November 2019

Progress is being made to develop a muscle-strengthening drug in SMA. Scholar Rock, Inc. has just announced interim results of a phase-2 clinical trial of their experimental drug SRK-015. SRK-015 aims to improve muscle strength in people with spinal muscular…

Read More

Risdiplam is safe and effective in treating SMA type 2 and 3

  • 11 November 2019

The world may soon have a new, highly potent treatment for spinal muscular atrophy as Roche today announced that the key clinical trial of risdiplam has met its primary endpoint. Based on the trial data, which are also supported by TreatSMA’s own observations, risdiplam appears safe and highly effective in improving muscle function of children, adolescents and adults with SMA types 2 and 3 who have participated in the SUNFISH trial.

We are thrilled!

Read More
Back To Top